Patents Assigned to Cevec Pharmaceutical GmbH
  • Recombinant glycoproteins with reduced antennary fucosylation
    Patent number: 11193156
    Abstract: The present invention relates to methods for reducing antennary fucosylation of complex N-glycans in recombinantly expressed glycoproteins, cell lines that can be used in said methods, respective recombinant glycoproteins, and methods for expressing the same in said cell lines.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: December 7, 2021
    Assignee: Cevec Pharmaceutical GmbH
    Inventors: Hanns-Martin Schmidt, Markus Ribbert, Gudrun Schiedner, Silke Wissing, Jens Wölfel
  • Recombinant Glycoproteins with Reduced Antennary Fucosylation
    Publication number: 20200032311
    Abstract: The present invention relates to methods for reducing antennary fucosylation of complex N-glycans in recombinantly expressed glycoproteins, cell lines that can be used in said methods, respective recombinant glycoproteins, and methods for expressing the same in said cell lines.
    Type: Application
    Filed: March 15, 2018
    Publication date: January 30, 2020
    Applicant: Cevec Pharmaceutical GmbH
    Inventors: Hanns-Martin Schmidt, Markus Ribbert, Gudrun Schiedner, Silke Wissing, Jens Wölfel
  • O-Glycan Sialylated Recombinant Glycoproteins and Cell Lines for Producing the Same
    Publication number: 20170342390
    Abstract: The present invention relates to cell lines that are genetically modified to overexpress a ?-galactoside ?-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as to respective recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.
    Type: Application
    Filed: December 15, 2015
    Publication date: November 30, 2017
    Applicant: Cevec Pharmaceutical GmbH
    Inventors: Silke Wissing, Jens Wölfel, Nicole Faust